Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance

Heart

Volumn 92, Issue 3, 2006, Pages 343-349

  Perugini, Enrica ^a   Rapezzi, C ^a   Piva, T ^a   Leone, O ^a   Bacchi Reggiani, L ^a   Riva, L ^a   Salvi, F ^b   Lovato, L ^a   Branzi, A ^a   Fattori, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GADOLINIUM PENTETATE; IMMUNOGLOBULIN LIGHT CHAIN; PREALBUMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HEART AMYLOIDOSIS; HEART FUNCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE BIOPSY; HEART MUSCLE CONTRACTILITY; HEART SIZE; HUMAN; HUMAN TISSUE; MALE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

AMYLOIDOSIS; CARDIOMYOPATHIES; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED;

EID: 33644533541     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.061911     Document Type: Article

References (25)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001;357:21-8.
3. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.
4. Beek AM, Kuhl HP, Bondarenko O, et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 2003;42:895-901.
5. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108:54-9.
6. Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;41:1561-7.
7. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:2156-64.
8. Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998;97:1802-9.
9. Moon JC, Mundy HR, Lee PJ, et al. Images in cardiovascular medicine. Myocardial fibrosis in glycogen storage disease type III. Circulation 2003;107:e47.
10. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5.
11. Fattori R, Rocchi G, Celletti F, et al. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 1998;136:824-30.
12. Trikas A, Rallidis L, Hawkins P, et al. Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis. Am J Cardiol 1999;84:1049-54.
13. Schiller NB, Shan PM, Crawford M, et al. Recommendation for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-67.
14. Appleton CP, Hatle LK, Popp RL. Demonstration of restrictive ventricular physiology by Doppler echocardiography. J Am Coll Cardiol 1988;11:757-68.
15. Siegel RJ, Roberts WC. Electrocardiographic observations in severe aortic valve stenosis: correlative necropsy study to clinical, hemodynamic, and ECG variables demonstrating relation of 12-lead QRS amplitude to peak systolic transaortic pressure gradient. Am Heart J 1982;103:210-21.
16. Cerqueira MD, Weissman MJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42.
17. Crotty TB, Li C-Y, Edwards WD, et al. Amyloidosis and endomyocardial biopsy: correlation of extent and pattern or deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol 1995;4:39-42.
18. Wesbey GE, Higgins CB, McNamara MT, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology 1984;153:165-9.
19. Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic ubstrate for premature cardiac death? J Am Coll Cardiol 2003;41:1568-72.
20. Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000;109:181-8.
21. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.
22. Smith TJ, Kyle R, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc 1984;59:547-55.
23. Bergstrom J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005;206:224-32.
24. Metzler JP, Fleckenstein JL, White CL 3rd, et al. MRI evaluation of amyloid myopathy. Skeletal Radiol 1992;21:463-5.
25. Benson L, Hemmingsson A, Ericsson A, et al. Magnetic resonance imaging in primary amyloidosis. Acta Radiol 1987;28:13-15.